Child & adolescent psychopharmacology news最新文献

{"title":"Antidepressant Update: New Findings from TORDIA, CAMS and the Adolescent Escitalopram (Lexapro) Trial","authors":"A. Robb","doi":"10.1521/CAPN.2009.14.1.1","DOIUrl":"https://doi.org/10.1521/CAPN.2009.14.1.1","url":null,"abstract":"","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"14 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2009-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2009.14.1.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychopharmacology in Preschoolers: A Brief Guide to Clinicians","authors":"Mini Tandon, J. Luby","doi":"10.1521/CAPN.2009.14.4.5","DOIUrl":"https://doi.org/10.1521/CAPN.2009.14.4.5","url":null,"abstract":"","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"14 1","pages":"5-7"},"PeriodicalIF":0.0,"publicationDate":"2009-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2009.14.4.5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Psychotropic Agents in Preschool Children: Issues in Practice, Research and Public Policy","authors":"J. Luby","doi":"10.1521/CAPN.2009.14.4.1","DOIUrl":"https://doi.org/10.1521/CAPN.2009.14.4.1","url":null,"abstract":"","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"23 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2009-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2009.14.4.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is There A Role For “Older” Agents in Child Psychopharmacology?","authors":"N. Carrey","doi":"10.1521/CAPN.2009.14.3.1","DOIUrl":"https://doi.org/10.1521/CAPN.2009.14.3.1","url":null,"abstract":"","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"14 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2009.14.3.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opinion: Secular Trends and Postgraduate Teaching Challenges in Psychopharmacology","authors":"D. Gardner","doi":"10.1521/CAPN.2009.14.3.7","DOIUrl":"https://doi.org/10.1521/CAPN.2009.14.3.7","url":null,"abstract":"Much has changed in the past two decades in terms of the pharmacotherapy of psychiatric disorders across the lifespan. It was just over 20 years ago that fluoxetine was first marketed in the United States and shortly thereafter clozapine made its remarkable return to patient care. But at the time these medications received marketing approvals from the FDA, Health Canada, and other nations’ regulatory agencies, we were not to know the impact they would have—on clinical practice, the pharmaceutical industry, psychotropic drug research, drug nomenclature, psychiatric nosology, perceptions of psychiatric patients and care, as well as education in clinical psychopharmacology. Prozac® quickly became a household word, supplanting Valium® as the best known psychotropic (Kramer, 1993). It also emerged as a lightning rod in child and adolescent psychopharmacology (Healy, 2003; Teicher et al., 1990). Prozac® was the first of several very successfully marketed SSRIs, which were found to be particularly effective in pediatric anxiety disorders. However, this therapeutic advance was overshadowed by these SSRIs’ uncertain benefit in adolescent depression and the early indications that they could promote rather than thwart suicidality in young patients (Research Unit on Pediatric Psychopharmacology, 2001; Kutcher & Gardner, 2008). The “awakenings” of chronically psychotic patients treated with clozapine generated hope and renewed interest in psychiatric practice, not unlike the pride described by psychiatrists 30 to 40 years earlier when the benefits of lithium, chlorpromazine, iproniazid, and imipramine were serendipitously uncovered, and heralded the modern psychopharmacologic era (Duckworth et al., 1997; Lambert, 1998). It was much easier to teach (and to learn) about psychotropic drugs when our understanding of the pathophysiological processes of mental illness were simple and the proposed mechanisms of how these drugs worked were uncomplicated. It was also easier to teach about psychotropics when their numbers were limited to a few distinct families with simply described pharmacological actions—dopamine antagonism for schizophreina, dopamine agonistic effects for attention, GABAmimetics for anxiety, and enhancement of serotonin or norepinephrine for depression. For bipolar disorder, we seemed content to have found lithium and other so-called mood stabilizers, even if their mechanisms remained mysterious. Never mind that the above psychotropic drugs were incompletely effective for most patients and completely ineffective for some, the proposed pharmacologic mechanisms meshed well with the pathophysiological proposals (though in many cases this was no coincidence) and this suited us just fine (Teicher, 1988). The neuroscientific basis of psychiatric disorders and investigations into the pharmacological effects of their treatments have exploded in the past 20 years coincident with advances in molecular genetics, molecular and cell biology, molecular pharmacolo","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"14 1","pages":"7-10"},"PeriodicalIF":0.0,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2009.14.3.7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focus: The Use of Psychotropic Drugs in Autism and Other Pervasive Developmental Disorders","authors":"L. Propper, H. Orlik","doi":"10.1521/CAPN.2009.14.2.1","DOIUrl":"https://doi.org/10.1521/CAPN.2009.14.2.1","url":null,"abstract":"","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"14 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2009.14.2.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autism and Sleep: Basics for the Clinician","authors":"M. Dell","doi":"10.1521/CAPN.2009.14.2.9","DOIUrl":"https://doi.org/10.1521/CAPN.2009.14.2.9","url":null,"abstract":"the QTc. The purpose of this study was to collect pilot data on the efficacy and safety of ziprasidone in adolescents with autism, focusing on safety issues of weight gain and QTc. Methods: Twelve adolescents with autism (mean age 14.5 +/1.8 years) were treated in a 6-week open pilot study. Ziprasidone dosage ranged from 20 to 160 mg/day (mean, 98.3 +/40.4 mg/day). The primary efficacy measure was the Clinical Global Impressions-Improvement item (CGI-I); other efficacy measures included the Aberrant Behavior Checklist and the Children’s Psychiatric Rating Scale. Results: Based on the CGI-I, 9 of 12 (75%) patients were treatment responders. Ziprasidone was weight neutral, and the QTc increased by a mean of 14.7 msec. Two subjects had acute dystonic reactions. Cholesterol decreased and prolactin remained the same.","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"14 1","pages":"9-11"},"PeriodicalIF":0.0,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2009.14.2.9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67089013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Black Box Warning and Its Unintended Consequences","authors":"A. Robb, L. Foster","doi":"10.1521/CAPN.2009.14.1.6","DOIUrl":"https://doi.org/10.1521/CAPN.2009.14.1.6","url":null,"abstract":"","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"14 1","pages":"6-9"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2009.14.1.6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescriptions Into Practice: Aripiprazole (Abilify): A Novel Atypical Antipsychotic Medication","authors":"N. Akhtar, A. Khan","doi":"10.1521/CAPN.2008.13.6.1","DOIUrl":"https://doi.org/10.1521/CAPN.2008.13.6.1","url":null,"abstract":"In the past, treatment of psychosis was centered on conventional agents, whose tolerability was limited by extrapyramidal side effects (EPS). The past decade has seen emergence of newer antipsychotic agents, first with clozapine and then with risperidone, olanzapine, quetiapine and ziprasidone. In general, while demonstrating similar efficacies to traditional agents, use of these compounds may be associated with lower risk of extrapyramidal symptoms (EPS) and possibly less cognitive impairment and better effects on negative symptoms. However, evolving evidence suggests that several drugs in this class may be associated with significant weight gain, lipid, and other metabolic abnormalities. Aripiprazole, a quinolinone derivative, is an atypical antipsychotic drug, displaying clinical efficacy similar to that of haloperidol and risperidone and superior to that of placebo in numerous clinical trials. Aripiprazole use is also associated with lower rate of clinically significant weight gain compared with other atypical antipsychotics. Patients receiving aripiprazole may experience EPS at a rate similar to that seen with placebo. Within the antipsychotic medication class, the introduction of aripiprazole may provide an alternative therapeutic option to traditional antipsychotics without some use limiting side effects of other atypical medications.","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"13 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2008.13.6.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescriptions Into Practice: Bupropion—A Guide to Rational Clinical Use","authors":"W. Daviss","doi":"10.1521/CAPN.2008.13.2.6","DOIUrl":"https://doi.org/10.1521/CAPN.2008.13.2.6","url":null,"abstract":"","PeriodicalId":89750,"journal":{"name":"Child & adolescent psychopharmacology news","volume":"13 1","pages":"6-10"},"PeriodicalIF":0.0,"publicationDate":"2008-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1521/CAPN.2008.13.2.6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67088493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}